MetaCap

CervoMed (CRVO) vs Lite Strategy (LITS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Lite Strategy (LITS) has outperformed CervoMed (CRVO) over the past year, losing 52.8% versus a loss of 83.6%. Over five years, CRVO leads with a -95.0% price change compared with -98.5% for LITS. Lite Strategy is the larger company by market cap ($24.0 million vs $22.1 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CRVO-83.56%LITS-52.79%
+18%-36%-90%
Nov 21, 20251 yearNov 20, 2026
CRVO-95.01%LITS-98.56%
+5%-49%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CRVO versus LITS key metrics
MetricCRVOLITS
Share price$1.46$0.8026
Market cap$22.09M$23.99M
1-day change+9.77%-4.03%
YTD return-81.52%-39.20%
1-year return-83.56%-52.79%
5-year return-95.01%-98.46%
EPS (TTM)$-2.65$-1.38
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$4.01M—
Revenue growth (YoY)-58.86%—
Net income (latest FY)$-26.97M$-71.15M
Operating margin-706.22%—
Net margin-673.06%—
52-week high$10.00$1.99
52-week low$1.27$0.69
Distance from 52-week high-85.40%-59.67%
Analyst consensusstrong_buy—
Avg. price target upside+954.79%—
Average volume489.10K524.33K
Shares outstanding15.13M29.88M
Employees155
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • LITS has outperformed CRVO by 30.8 percentage points over the past year.

About CervoMed

CRVO stock →

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a.

Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees

About Lite Strategy

LITS stock →

Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees

CRVO vs LITS FAQ

Which is bigger, CervoMed or Lite Strategy?

Lite Strategy (LITS) is larger, with a market capitalization of $23.99M compared with $22.09M for CervoMed (CRVO).

Which stock has performed better over the past year, CRVO or LITS?

LITS returned -52.79% over the past 12 months, compared with -83.56% for CRVO (price return, excluding dividends). Past performance does not predict future results.

Are CervoMed and Lite Strategy in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons